ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1588

Relation of Foot and Ankle Pain to Worsening Knee Pain: The MOST Study
Abstract Number: 0220

Relation of Knee Extensor Power to Worsening Cartilage Damage in the Knee: The MOST Study
Abstract Number: 0980

Relationship Between Paraoxonase-1 Genotype, Activity, and Malignancies in Patients with RA Receiving Tofacitinib
Abstract Number: 1660

Relationship Between Risk of New Onset Diabetes Mellitus and Exposure to Individual Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study
Abstract Number: 1822

Relationships Between Dermatologic Symptoms and Health-related Quality of Life in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Abstract Number: 1807

Relationships Between Fatigue and Hemoglobin/C-Reactive Protein Levels and Associations Between Fatigue and Clinical Response in Patients with Active Psoriatic Arthritis: Results from Two Randomized Controlled Trials of Guselkumab (TREMFYA®)
Abstract Number: 0799

Relationships of Rheumatology Care and Patient Experiences to Rheumatoid Arthritis Remission
Abstract Number: 0010

Relaxed Peripheral Tolerance Drives Broad de Novo Autoreactivity in Severe COVID-19
Abstract Number: 1365

Release of High-Mobility Group Box-1 After an Raynaud’s Attack Potentially Leads to Fibroblast Activation and Interferon-γ Induced Protein-10 Production in Systemic Sclerosis
Abstract Number: 0167

Reliability of a Novel Pediatric Joint-Specific Scoring System for the Elbow, Wrist and Finger Joints
Abstract Number: 0792

Remission Rates of Patients with Rheumatoid Arthritis in a Tertiary Care
Abstract Number: 0462

Remotely Delivered Cognitive Behavioural and Personalised Exercise Interventions Reduce Fatigue Severity and Impact in Inflammatory Rheumatic Diseases: Results from a Multi-centre Randomised Controlled Parallel Group Trial
Abstract Number: 1137

REMS Technology for the Assessment of Bone Health in a Male Population
Abstract Number: 0875

Renal Function, Adherence and Low Hydroxychloroquine Dosing Predict HCQ Blood Levels and Lupus Disease Activity
Abstract Number: 0304

Renal Involvement in Sjőgren’s Syndrome: Predictors and Impact on Patient Outcome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].